GlassScriptPhysician profile
Richard J Feingold
NPI 1629070362
$1,963.79
in general payments reported to CMS, 2019-2025
22 companies · $219 in 2025
The $219 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $616 · 2020: $47.00 · 2021: $247 · 2022: $342 · 2023: $239 · 2024: $254 · 2025: $219.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $712.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $712.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $586.41 | 2019-2024 | |
| Pfizer INC. | $332.69 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $190.37 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $150.42 | 2019-2025 | Camzyos |
| Astellas Pharma US INC | $110.60 | 2019-2021 | |
| Amgen INC. | $75.09 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $74.66 | 2019 | |
| Amarin Pharma, INC. | $59.47 | 2019-2021 | |
| Abbott Laboratories | $53.51 | 2021-2023 | Aveir |
| Novo Nordisk INC | $44.82 | 2022-2025 | Rybelsus, Ozempic |
| Gilead Sciences, INC. | $40.26 | 2019 | |
| Alnylam Pharmaceuticals INC. | $39.67 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $28.36 | 2020-2021 | |
| Boston Scientific Corporation | $25.98 | 2024 | Latitude Communicator Power Supply |
| Heartflow, INC. | $24.11 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $24.07 | 2021 | |
| Inspire Medical Systems, INC. | $22.50 | 2024 | Inspire |
| Biotronik INC. | $20.00 | 2022 | |
| Merck Sharp & Dohme LLC | $17.27 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.29 | 2025 | Jardiance |
| Atricure, INC. | $15.11 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $12.13 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Feingold listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.